A Phase II Trial of Xevinapant in Combination with Post-Operative Cisplatin and Radiotherapy for High Risk Head and Neck Cancer

被引：0
|
作者：
Yu, Y. [1 ]
Ganly, I. [2 ]
Sherman, E. [3 ]
Lee, N. Y. [4 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, New York, NY USA
[2] Mem Sloan Kettering Canc Ctr, Dept Surg, New York, NY USA
[3] Mem Sloan Kettering Canc Ctr, Dept Med Oncol, New York, NY USA
[4] Mem Sloan Kettering Canc Ctr, New York, NY USA
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2024年 / 118卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
123
引用
收藏
页码：E25 / E25
页数：1
相关论文
共 50 条
  • [31] Phase I trial of concomitant hyperfractionated radiotherapy with docetaxel and cisplatin for locally advanced head and neck cancer
    Allal, AS
    Zwahlen, D
    Becker, M
    Dulguerov, P
    Mach, N
    CANCER JOURNAL, 2006, 12 (01): : 63 - 68
  • [32] Phase I trial of pemetrexed in combination with cetuximab and concurrent radiotherapy in patients with head and neck cancer
    Argiris, A.
    Karamouzis, M. V.
    Smith, R.
    Kotsakis, A.
    Gibson, M. K.
    Lai, S. Y.
    Kim, S.
    Branstetter, B. F.
    Shuai, Y.
    Romkes, M.
    Wang, L.
    Grandis, J. R.
    Ferris, R. L.
    Johnson, J. T.
    Heron, D. E.
    ANNALS OF ONCOLOGY, 2011, 22 (11) : 2482 - 2488
  • [33] TrilynX: A phase 3 trial of xevinapant and concurrent chemoradiation for locally advanced head and neck cancer.
    Bourhis, Jean
    Burtness, Barbara
    Licitra, Lisa F.
    Nutting, Christopher
    Schoenfeld, Jonathan D.
    Sarkouh, Rafik Ait
    Bouisset, Florilene
    Nauwelaerts, Heidi
    Urfer, Yulia
    Zanna, Claudio
    Cohen, Ezra E. W.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [34] Randomized Phase II/III Trial of Post-operative Chemoradiotherapy Comparing 3-Weekly Cisplatin with Weekly Cisplatin in High-risk Patients with Squamous Cell Carcinoma of Head and Neck: Japan Clinical Oncology Group Study (JCOG1008)
    Kunieda, Futoshi
    Kiyota, Naomi
    Tahara, Makoto
    Kodaira, Takeshi
    Hayashi, Ryuichi
    Ishikura, Satoshi
    Mizusawa, Junki
    Nakamura, Kenichi
    Fukuda, Haruhiko
    Fujii, Masato
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2014, 44 (08) : 770 - 774
  • [35] Trilynx: A Phase 3 Trial of Xevinapant and Concurrent Chemoradiotherapy (CRT) for Locally Advanced Head and Neck Cancer
    Schoenfeld, J. D.
    Cohen, E.
    Nutting, C. M.
    Licitra, L.
    Burtness, B.
    Omar, M.
    Bouisset, F.
    Nauwelaerts, H.
    Urfer, Y.
    Zanna, C.
    Bourhis, J., Sr.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 112 (05): : E20 - E21
  • [36] The impact of national holiday on post-operative radiotherapy of squamous cell carcinoma of head and neck reply
    Ali, Tooba
    Hina, Mariam
    Khan, Laraib
    Qureshi, Bilal Mazhar
    Hafiz, Asim
    Abbasi, Ahmed Nadeem
    CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY, 2024, 46
  • [37] Concomitant cisplatin and radiotherapy in a conventional and modified fractionation schedule in locally advanced head and neck cancer: A randomised phase II EORTC trial
    Bartelink, H
    Van den Bogaert, W
    Horiot, JC
    Jager, J
    van Glabbeke, M
    EUROPEAN JOURNAL OF CANCER, 2002, 38 (05) : 667 - 673
  • [38] A phase II study of combination chemotherapy with capecitabine and cisplatin in patients with metastatic or recurrent head and neck cancer
    Won, Y. W.
    Park, Y. H.
    Ahn, M. J.
    Park, K.
    EJC SUPPLEMENTS, 2009, 7 (02): : 491 - 491
  • [39] Hyperfractionated accelerated radiotherapy in combination with weekly cisplatin for locally advanced head and neck cancer
    Beckmann, GK
    Hoppe, F
    Pfreundner, L
    Flentje, MP
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2005, 27 (01): : 36 - 43
  • [40] Mature results of a phase I trial of bortezomib, cisplatin, and radiotherapy for advanced or recurrent head and neck cancer.
    Axelrod, R. S.
    Ahn, P. H.
    Kubicek, G. J.
    Anne, P. R.
    Cognetti, D.
    Dicker, A.
    Machtay, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345